Lonza Group AG stock (CH0013841017): Biopharma services powerhouse for US biotech boom

Lonza Group AG continues to play a pivotal role in the biopharmaceutical sector, providing essential contract development and manufacturing organization (CDMO) services to biotech and pharma companies worldwide. The company reported steady progress in its core segments during its latest full-year results for 2025, published on February 27, 2026, with revenue reaching CHF 8.7 billion, up 9% at constant exchange rates from the prior year, according to Lonza IR as of 02/27/2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Lonza Group AG: core business model

Lonza Group AG operates as a global CDMO, specializing in the development and manufacturing of biologics, small molecules, and advanced therapies like cell and gene treatments. With facilities across Switzerland, the US, and Europe, the company partners with biotech innovators from early-stage development through commercial-scale production. This end-to-end service model reduces time-to-market for clients, particularly in the high-growth areas of monoclonal antibodies and mRNA technologies.

The firm's diversified revenue streams include its Biologics unit, which contributes over 60% of sales, focusing on mammalian cell culture-based production. Lonza's investments in modular facilities and biosafety enhancements position it to meet stringent regulatory standards from the FDA and EMA, making it a preferred partner for US-listed biotechs navigating complex approvals.

Main revenue and product drivers for Lonza Group AG

Biologics manufacturing remains the primary revenue engine, with 2025 sales in this segment growing 12% to CHF 5.3 billion, driven by demand for GLP-1 agonists and oncology drugs, as detailed in the annual report published February 27, 2026, via Lonza IR as of 02/27/2026. Cell & Gene Technologies added CHF 1.2 billion, benefiting from partnerships in viral vector production.

Key clients include major US biopharma players, with Lonza's US sites in Portsmouth, New Hampshire, and Houston, Texas, serving as hubs for North American operations. Capsugel's oral drug delivery systems provide steady mid-single-digit growth, offsetting cyclicality in larger projects.

Industry trends and competitive position

The CDMO market is projected to expand at 12% CAGR through 2030, fueled by biologics comprising 70% of new drug approvals, per EvaluatePharma as of 01/2026. Lonza holds a top-tier position alongside rivals like Catalent and Samsung Biologics, distinguished by its scale in microbial and mammalian manufacturing.

In the US, where biotech funding rebounded in 2025 with $45 billion in VC investments, Lonza's capacity expansions support the pipeline of 1,200+ clinical-stage assets, enhancing its competitive moat through long-term contracts averaging five years.

Why Lonza Group AG matters for US investors

Lonza's deep ties to the US biotech ecosystem make it relevant for American portfolios. Over 40% of its revenue derives from North America, with key contracts for mRNA vaccines and ADCs tied to US innovation hubs like Boston and San Francisco. The company's ADRs trade OTC in the US, offering indirect exposure to Swiss-listed shares.

Amid US healthcare spending exceeding $4.5 trillion annually, Lonza benefits from trends in personalized medicine and outsourcing, where 60% of biotechs rely on CDMOs, positioning it as a leveraged play on sector growth without direct R&D risk.

Conclusion

Lonza Group AG demonstrates resilience in the CDMO space, with 2025 results underscoring strength in biologics and advanced modalities amid robust biotech demand. US investors gain exposure to global biopharma outsourcing trends through its North American footprint and client roster. Ongoing capacity builds signal confidence in sustained pipeline growth, though execution amid supply chain pressures warrants monitoring.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.